Disarming oxidized lipids: AAV-delivered antibody neutralization as an emerging strategy against ALS
Molecular Therapy Advances · 2026-12 · 34 (4) · 201879
DOI: 10.1016/j.omta.2026.201879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Sergi Verdés und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience (INc), and Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease affecting motor neurons (MNs) and the neuromuscular axis. Despite decades of research on its molecular trigger and pathological mechanisms, and the search for effective disease-modifying therapies, both questions remain largely unknown. A common feature of ALS, present in 97% of cases, is the mislocalization, aggregation, and functional disruption of TAR DNA-binding protein 43 (TDP-43),1 yet the upstream trigger of this proteinopathy is poorly understood.
Autor:innen und Institutionen
- Institute of Neuroscience (INc), and Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Unitat Mixta UAB-VHIR, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Zitieren
APA
Verdés, S., & Bosch, A. (2026). Disarming oxidized lipids: AAV-delivered antibody neutralization as an emerging strategy against ALS. Molecular Therapy Advances, 34(4), 201879. https://doi.org/10.1016/j.omta.2026.201879
Vancouver
Verdés S, Bosch A. Disarming oxidized lipids: AAV-delivered antibody neutralization as an emerging strategy against ALS. Molecular Therapy Advances. 2026;34(4):201879. doi:10.1016/j.omta.2026.201879
BibTeX
@article{Verds2026,
author = {Verdés, Sergi and Bosch, Assumpció},
title = {Disarming oxidized lipids: AAV-delivered antibody neutralization as an emerging strategy against ALS},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201879},
doi = {10.1016/j.omta.2026.201879}
}
EUVIMED